Is compounded semaglutide safe?

What the FDA has actually recorded

The starting point is what the agency says about compounded drugs generally: "Compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed." Nothing about compounded semaglutide changes that, including when it comes from an FDA-registered 503B outsourcing facility.

On this specific drug, the FDA publishes a running count. As of 31 May 2026 it had received 990 reports of adverse events associated with compounded semaglutide, alongside more than 730 for compounded tirzepatide. The agency adds an important caveat: "federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported."

What the FDA does not publish is how many of those reports involved hospitalisation or death. It says only that some events required hospitalisation. Anyone quoting a death toll for compounded semaglutide is not quoting the FDA.

For scale: an adverse-event report is not proof that the drug caused the event, and 990 reports is not 990 injuries. It is the number of times someone thought the connection was worth reporting, in a system the agency itself describes as incomplete.

Context that cuts the other way: reports of medication errors across all drugs rose from just over 2,000 in 2020 to more than 25,000 in 2025, and GLP-1s are now among the most-prescribed medicines in the country. Some of this rise is the category growing, not the category being uniquely dangerous.

The biggest documented risk is the dose, not the drug

In July 2024 the FDA published an alert about dosing errors with compounded injectable semaglutide that it still lists as current. It is the most concrete safety document in this whole area, and what it describes is a measurement problem.

A brand-name pen delivers one fixed dose when you click it. A compounded product is usually a multi-dose vial at a concentration the pharmacy chose, from which you draw each dose yourself with an insulin syringe. That means three units of measurement are in play at once — milligrams, millilitres, and the "units" marked on the syringe — and the FDA found that people were confusing them.

• Patients told to draw 5 units (0.05 mL) drew 50 units instead — a tenfold overdose.
• A prescriber wrote "25 units" when the intended dose was 0.25 mg, which is 5 units — a fivefold overdose.
• Another wrote 20 units when 2 units were intended — a tenfold overdose, which reached three patients.
• Overall, the FDA describes patients who "administered five to 20 times more than the intended dose".

Reported effects of these overdoses: "gastrointestinal effects (e.g., nausea, vomiting, abdominal pain), fainting, headache, migraine, dehydration, acute pancreatitis and gallstones", some requiring hospital care. The FDA names the root cause as "confusion between different units of measurement (e.g., milliliters, milligrams and 'units')", compounded by vials of varying concentrations and by patients being new to drawing up an injection.

What is in the vial, and where it came from

The second class of risk is the ingredient itself. Three things the FDA has flagged are worth knowing by name.

Salt forms. Some compounders have used semaglutide sodium or semaglutide acetate rather than the semaglutide base used in approved products. The FDA's position is blunt: these "are different active ingredients than are used in the approved drugs", and the agency is "not aware of any lawful basis for their use in compounding". If a provider cannot tell you which form it uses, that is an answerable question they are not answering.

Where the raw ingredient came from. Since September 2025 the FDA has maintained a "Green List" of acceptable GLP-1 active-ingredient suppliers, backed by Import Alert 66-80, which lets it detain shipments from unlisted sources at the border. The announcement cited dosing errors, unapproved salt forms and adverse events including hospitalisations as the reasons.

Counterfeits and "research" peptides. Separately from legitimate compounding, semaglutide is sold online by sellers with no pharmacy involvement, often labelled "for research purposes only" or "not for human consumption" while being shipped with dosing instructions. The FDA warns that counterfeit products "could contain the wrong ingredients, contain too little, too much or no active ingredient at all or other harmful ingredients, and are illegal". These are not compounded medicines and nothing on this page applies to them.

The side effects of semaglutide itself

Everything above is about the compounding. The drug's own effects are the same molecule's effects, and those are documented in the approved labels — which is the best available evidence for what a compounded version will do, even though it was not the product studied.

In the Wegovy trials at the 2.4 mg dose, nausea affected 44% of patients against 16% on placebo, diarrhea 30% against 16%, vomiting 24% against 6%, constipation 24% against 11% and abdominal pain 20% against 10%. Headache, fatigue, indigestion, dizziness and bloating each affected 7–14%. In the Ozempic trials at lower doses the rates are lower: nausea 15.8% at 0.5 mg and 20.3% at 1 mg, against 6.1% on placebo.

Most of this is worst in the weeks after a dose increase and settles. What matters is knowing which effects are not the ordinary ones.

• Boxed warning. In rodents, semaglutide caused dose-dependent thyroid C-cell tumors. Whether it does so in humans is unknown. The warning applies to any semaglutide product, compounded or not.
• Contraindicated if you or a family member has had medullary thyroid carcinoma, if you have Multiple Endocrine Neoplasia syndrome type 2, or if you have had a serious allergic reaction to semaglutide.
• Seek care for persistent severe abdominal pain, especially radiating to the back (possible pancreatitis); pain in the upper right abdomen with fever or jaundice (gallbladder); vomiting or diarrhea you cannot keep ahead of (dehydration can cause acute kidney injury); or swelling of the face, lips or throat and difficulty breathing (serious allergic reaction).
• Tell any surgeon or anesthetist that you take a GLP-1. These drugs slow stomach emptying, and the labels warn about food being aspirated into the lungs during general anesthesia or deep sedation.
• If you have diabetic retinopathy, tell the prescriber: rapid improvements in blood sugar can worsen it, and the labels carry a specific warning.
• If you also take insulin or a sulfonylurea, the combination raises the risk of hypoglycemia and usually needs a dose adjustment.

What nobody can tell you

Three gaps are worth naming plainly, because filling them with reassurance is how this topic usually gets written.

No compounded semaglutide product has been through a clinical trial. Every weight-loss percentage published for semaglutide belongs to Wegovy — a specific formulation, at defined strengths, in a specific device. A pharmacy-made version at a different concentration may perform the same way. Nobody has tested it.

Quality varies by pharmacy, and you cannot see it. A 503A pharmacy is overseen by a state board and is not subject to the FDA's manufacturing rules; a 503B facility is FDA-inspected and must follow good manufacturing practice. Both make unapproved products. Which one filled your vial is knowable, and worth knowing.

The reporting is incomplete by design. Because most compounding pharmacies are not required to report adverse events to the FDA, the 990 figure is a floor, not a measurement.

How to make it safer if you use it

None of this means every compounded product is dangerous. It means the checks that are performed for you with an approved drug have to be performed by you, or by someone you trust, with this one.

• Get the dose in writing, in the same units you will measure. If the prescription says milligrams and the syringe says units, ask for the conversion in writing before the first injection, and confirm the concentration printed on your vial matches it.
• Check the concentration every time a new vial arrives. Pharmacies change concentrations; the same "10 units" can be a different dose from a different vial.
• Ask which pharmacy made it and in which form. Semaglutide base, not a sodium or acetate salt, from a supplier on the FDA's Green List.
• Do not increase the dose faster than the prescriber set. The FDA has specifically flagged patients taking doses beyond the approved label — more per dose, more often, or escalating faster.
• Store it as instructed and never share a pen or syringe, even with a new needle.
• Report side effects. You can report directly to the FDA through MedWatch; with a compounding pharmacy, your report may be the only one the agency receives.

How to tell whether the provider selling it is legitimate

"Is this company legit?" is the most common question we are asked about compounded semaglutide, and it is usually the right question — in this market the seller is a bigger variable than the molecule.

The signals that actually separate a licensed telehealth service from a reseller are the same ones the FDA's enforcement has focused on:

• A clinician licensed in your state reviews your intake before a prescription exists. Instant approval is not a feature.
• The compounding pharmacy is named, and is findable with your state board of pharmacy or on the FDA's register of outsourcing facilities.
• The product is described accurately. Claims that it is "the same as Wegovy" or "FDA-approved" are exactly what the FDA cited when it wrote to 30 telehealth companies in February 2026, and to a first group including Hims & Hers in September 2025.
• The company is identifiable — a real corporate name, a US address, a working way to reach a human.
• Price, dose and cancellation terms are published before you pay, including what happens to the price when your dose rises.
• Its public record is checkable. FDA warning letters, state actions, FTC cases and lawsuits are public documents.

We do that check for every provider in the directory, with dates and source links, in each profile's "Is it legit?" section — including providers with regulatory history against them. If a company you are looking at is not there yet, the checklist above is the same one we use. See how we rank for the method.